雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

New therapeutic strategy for amyotrophic lateral sclerosis Yasuto Itoyama 1 1Department of Neurology, Tohoku University School of Medicine Keyword: 筋萎縮性側索硬化症 , ALS , Cu/Zn superoxide dismutase , SOD1 , 肝細胞増殖因子 , HGF , ALSトランスジェニックラット , 神経幹細胞移植 pp.913-919
Published Date 2006/12/10
DOI https://doi.org/10.11477/mf.1431100412
  • Abstract
  • Look Inside
  • Reference

 Amyotrophic lateral sclerosis(ALS)is a late onset, slowly progressive and ultimately fatal neurodegenerative disease, caused by the loss of motor neurons in the brain and spinal cord. ALS is thought to be one of the most relentless neurological diseases. The cause of ALS remains unknown, but a mutant Cu/Zn superoxide dismutase(SOD1)gene is thought to be one of most likely causes. Unfortunately, there are no effective medicines for this disease. In order to develop a new therapeutic method or medicines for ALS, we invented a new ALS rat model, SOD1 transgenic rat, which is 20 times larger in size than the mouse ALS model. Hepatocyte growth factor(HGF), which was discovered by Professor Nakamura in Osaka University, is known to have a potent neurotrophic effect on motor neurons. Our recent experimental trial in which HGF was continuously administered to ALS rats by an intrathecal route after the onset of disease showed significant effects on the clinical course and histopathological findings. ALS rats in the HGF group survived 1.6 times longer than those in the placebo group. For the clinical application of HGF for patients with ALS, we are now determining the safe doses and duration of HGF medication or possible side effects using marmosets. Additionally, genetical treatment and neural stem cell transplantation are discussed as a promising new treatment for ALS.


Copyright © 2006, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1243 印刷版ISSN 0001-8724 医学書院

関連文献

もっと見る

文献を共有